A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs

Edward M. Wolin,Barbara Jarzab,Barbro Eriksson,Thomas Walter,Christos Toumpanakis,Michael A. Morse,Paola Tomassetti,Matthias M. Weber,David R. Fogelman,John Ramage,Donald Poon,Jerry Huang,Michelle Hudson,Jiang Li,Janice L. Pasieka,Abakar Mahamat,Fredrik Swahn,John Newell-Price,Was Mansoor,Kjell Öberg

A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs

2014

A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs

Keywords:

Endocrinology
Internal medicine
Pasireotide
Phases of clinical research
Neuroendocrine tumors
Somatostatin
Disease
Octreotide
Medicine
in patient
octreotide lar
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations